# STOMP OUT: A Phase 2 Study To Evaluate The Effects Of Ivonescimab In Patients With Unresectable/Metastatic Adrenocortical Carcinoma (ACC) Or Unresectable Pheochromocytoma/Paraganglioma (PPGL)

> **NCT07743138** · PHASE2 · NOT_YET_RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 20 (estimated)

## Conditions studied

- Adrenocortical Carcinoma
- Pheochromocytoma
- Paraganglioma

## Interventions

- **DRUG:** Ivonescimab

## Key facts

- **NCT ID:** NCT07743138
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2027-02-07
- **Primary completion:** 2028-05-01
- **Final completion:** 2030-05-01
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-09-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07743138

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07743138, "STOMP OUT: A Phase 2 Study To Evaluate The Effects Of Ivonescimab In Patients With Unresectable/Metastatic Adrenocortical Carcinoma (ACC) Or Unresectable Pheochromocytoma/Paraganglioma (PPGL)". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07743138. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*